Start Time: 16:30 January 1, 0000 5:36 PM ET

PTC Therapeutics, Inc. (NASDAQ:PTCT)

Q1 2022 Earnings Conference Call

May 03, 2022, 16:30 PM ET

Company Participants

Stuart Peltz - Founder and CEO

Matthew Klein - COO

Eric Pauwels - Chief Business Officer

Emily Hill - CFO

Kylie O’Keefe - SVP, Global Commercial and Corporate Strategy

Conference Call Participants

Eric Joseph - JPMorgan

Rick Krause - Cantor Fitzgerald

Brian Abrahams - RBC Capital Markets

Joseph Thome - Cowen and Company

Gena Wang - Barclays

Robyn Karnauskas - Truist Securities

Alex Sklar - Raymond James

Colin Bristow - UBS

Operator

Ladies and gentlemen, thank you for standing by. Welcome to the PTC First Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions].

I would now like to turn the call over to your host, Kyle O’Keefe. You may begin.

Kylie O’Keefe

Good afternoon and thank you for joining us today to discuss the PTC Therapeutics first 2022 corporate update and financial results. I am joined today by our Chief Executive Officer, Stuart Peltz; our Chief Operating Officer, Matthew Klein; our Chief Business Officer, Eric Pauwels; and our Chief Financial Officer, Emily Hill.

Today's call will include forward-looking statements based on current expectations. Please take a moment to review the slide posted on our Investor Relations Web site in conjunction with the call, which contains our forward-looking statements. Our actual results could materially differ from these forward-looking statements as such statements are subject to risks that can materially and adversely affect our business and results of operations.

For a detailed description of applicable risks and uncertainties, we encourage you to review the company's most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the Securities and Exchange Commission as well as the company's other SEC filings. We will disclose certain non-GAAP information during this call. Information regarding our use of GAAP to non-GAAP financial measures and a reconciliation of GAAP to non-GAAP is available in today's earnings release.

With that, let me pass the call over to our CEO, Stuart Peltz. Stu?

Stuart Peltz

Thanks, Kyle. Good afternoon and thanks for joining today. I'm excited to share PTC's first quarter results, but first an update on what I expect to be a transformative year for the company. On this, PTC has developed therapeutics to help treat patients with rare disorders while producing revenue to provide value for all of our stakeholders.